Alimera Sciences, Inc. (ALIM)
ALIM Price and Sentiment
ALIM Latest news
Analysts Estimate Alimera Sciences (ALIM) to Report a Decline in Earnings: What to Look Out for
2 hours agoAlimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALIM Stock: Why It Increased Today
2021-10-13 21:14The stock price of Alimera Sciences Inc (NASDAQ: ALIM) increased by over 6% today. This is why it happened.
Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN® to Significantly Reduce Treatment Burden in Patients with Diabetic Macular Edema
2021-10-13 08:00PALADIN Study Data Presented at the American Society of Retina Specialists Shows That Post-ILUVIEN, the Percentage of Eyes Receiving One Yearly Treatment or Less Increased 3.2-Fold Compared to Pre-ILUVIEN
Alimera Sciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
2021-09-02 16:30ATLANTA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer., announces today that Chief Executive Officer Rick Eiswirth will present at the 23rd Annual H.C. Wainwright Global Investment Conference which is being held virtually from September 13 – 15, 2021.
Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN® for DME in Belgium
2021-08-24 08:00ATLANTA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, received pricing and reimbursement approval for ILUVIEN® for diabetic macular edema (DME) in Belgium from the National Institute for Health and Disability Insurance (INAMI). Pricing and reimbursement approval was sought and secured by Alimera's distribution partner in France and the Benelux region, Horus Pharma S.A.S. (Horus). Horus is currently in the launch phase in Belgium.
New Strong Sell Stocks for August 19th
2021-08-19 10:45ALIM, BEEM, CDR, ENTX, and IDEX have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2021.
Alimera Sciences' (ALIM) CEO Rick Eiswirth on Q2 2021 Results - Earnings Call Transcript
2021-08-14 02:52Alimera Sciences' (ALIM) CEO Rick Eiswirth on Q2 2021 Results - Earnings Call Transcript
Alimera Sciences (ALIM) Q2 Earnings and Revenues Miss Estimates
2021-08-13 10:52Alimera Sciences (ALIM) delivered earnings and revenue surprises of -39.20% and -6.85%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Alimera Sciences Q2 Earnings
2021-08-13 09:41Shares of Alimera Sciences (NASDAQ:ALIM) moved higher by 5.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 252.94% year over year to $0.78, which missed the estimate of $1.06.
Alimera Sciences Announces Second Quarter 2021 Financial Results
2021-08-13 08:00ATLANTA, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced financial results for the second quarter of 2021. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.